News and Media

More On Colucid

Our pipeline of novel CNS compounds includes lasmiditan, a first in class Neurally Acting Anti-Migraine Agent (NAAMA).


About Migraines

Approximately 36 million Americans have migraines (13% of adult population)

  • 18% of women and 6% of men experience migraines
  • Most common in working population from 25 to 55 years old
  • Direct medical expenditures exceed $11 billion per year in U.S.

About Colucid

CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company's investors include Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures.

Learn More About CoLucid